Blocking the MET signaling by the MET inhibitors, PF-2341066, or by specific MET RNAi had antiproliferative effects and reduced tumor metastasis in ovarian cancer cells, possibly by suppressing MET-dependent PI3-K/AKT and RAF/MAPK signaling pathways [13,14]. This evidence concerns the gene MET and ovarian carcinoma.